Pravastatin Attenuates Left Ventricular Remodeling and Diastolic Dysfunction in Angiotensin II-Induced Hypertensive Mice
Authors:
- 1 January 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 51 (1) , 62-70
Abstract
Background: A substantial proportion of patients with heart failure have a normal ejection fraction and diastolic dysfunction. However, there are few data available to guide the therapy of these patients. The effects of statins on cardiac remodeling are well documented in animal models and it is reported that statin therapy revealed a survival benefit in patients with diastolic heart failure (DHF). However, the exact mechanisms of statins possibly explaining the decreased cardiovascular morbidity and mortality in patients with DHF have not been elucidated. Methods: We used 8-week-old male C57BL/6J mice, in which angiotensin II was subcutaneously infused for 4 weeks to mimic cardiac remodeling and fibrosis. They were treated with either normal saline or pravastatin in daily doses, which did not lower the serum cholesterol levels and blood pressure. Results: Pravastatin improved diastolic dysfunction in angiotensin II-induced hypertensive mice, which was associated with the amelioration of left ventricular hypertrophy and remodeling. However, statin treatment showed no effect on the increased systolic blood pressure or cholesterol levels by angiotensin II infusion. The cardioprotective effects of pravastatin were closely associated with the downregulation of collagen I, transforming growth factor-beta, matrix metalloproteinases-2 and -3, atrial natriuretic factor, interleukin-6, tumor necrosis factor-alpha, ROCK1 gene expression, and the upregulation of endothelial nitric oxide synthase gene expression. Conclusions: The beneficial effects of pravastatin on DHF and structural remodeling are through cholesterol- independent mechanism of statins or “pleiotropic” effects of statins involving improving or restoring endothelial function and decreasing vascular inflammation. These findings suggest the potential involvement of ROCK1. Thus, treatment with pravastatin might be beneficial in patients with DHF.Keywords
This publication has 36 references indexed in Scilit:
- Rho Kinase (ROCK) InhibitorsJournal of Cardiovascular Pharmacology, 2007
- Pravastatin Prevents Myocardium from Ischemia-Induced Fibrosis by Protecting Vascular Endothelial Cells Exposed to Oxidative StressCardiovascular Drugs and Therapy, 2006
- Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosisThe FASEB Journal, 2006
- Decreased Perivascular Fibrosis but Not Cardiac Hypertrophy in ROCK1 +/− Haploinsufficient MiceCirculation, 2005
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein CholesterolThe American Journal of Cardiology, 2005
- Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart FailureCirculation, 2005
- Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive ratsClinical Science, 2005
- In Vivo Echocardiographic Detection of Cardiovascular Lesions in Apolipoprotein E-Knockout Mice Using a Novel High-Frequency High-Speed Echocardiography Technique.Circulation Journal, 2002
- Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology, 2001